BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 37199632)

  • 21. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation.
    Luo J; Luckenbaugh L; Hu H; Yan Z; Gao L; Hu J
    mBio; 2020 Feb; 11(1):. PubMed ID: 32071277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion of hepatitis B virus relaxed circular to covalently closed circular DNA is supported in murine cells.
    Wei L; Cafiero TR; Tseng A; Gertje HP; Berneshawi A; Crossland NA; Ploss A
    JHEP Rep; 2022 Sep; 4(9):100534. PubMed ID: 36035363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of Hepatitis B Virus cccDNA Formation.
    Wei L; Ploss A
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PCR mediated recombination impacts the analysis of hepatitis B Virus covalently closed circular DNA.
    Suspène R; Thiers V; Vartanian JP; Wain-Hobson S
    Retrovirology; 2016 Dec; 13(1):84. PubMed ID: 27998270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B Virus Core Protein Is Not Required for Covalently Closed Circular DNA Transcriptional Regulation.
    Zhong Y; Wu C; Xu Z; Teng Y; Zhao L; Zhao K; Wang J; Wang W; Zhan Q; Zhu C; Chen X; Liang K; Cheng X; Xia Y
    J Virol; 2022 Nov; 96(21):e0136222. PubMed ID: 36226986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation.
    Marchetti AL; Guo H
    Cells; 2020 Nov; 9(11):. PubMed ID: 33172220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
    Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses.
    Guo H; Mao R; Block TM; Guo JT
    J Virol; 2010 Jan; 84(1):387-96. PubMed ID: 19864387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct dual antiviral mechanism that enhances hepatitis B virus mutagenesis and reduces viral DNA synthesis.
    McDaniel YZ; Patterson SE; Mansky LM
    Antiviral Res; 2019 Oct; 170():104540. PubMed ID: 31247245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Untying relaxed circular DNA of hepatitis B virus by polymerase reaction provides a new option for accurate quantification and visualization of covalently closed circular DNA.
    Kamiya N; Sugimoto T; Abe-Chayama H; Akiyama R; Tsuboi Y; Mogami A; Imamura M; Hayes CN; Chayama K
    J Gen Virol; 2022 Feb; 103(2):. PubMed ID: 35130138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Host transcription factor Speckled 110 kDa (Sp110), a nuclear body protein, is hijacked by hepatitis B virus protein X for viral persistence.
    Sengupta I; Das D; Singh SP; Chakravarty R; Das C
    J Biol Chem; 2017 Dec; 292(50):20379-20393. PubMed ID: 29046350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viral DNA Binding Protein SUMOylation Promotes PML Nuclear Body Localization Next to Viral Replication Centers.
    Stubbe M; Mai J; Paulus C; Stubbe HC; Berscheminski J; Karimi M; Hofmann S; Weber E; Hadian K; Hay R; Groitl P; Nevels M; Dobner T; Schreiner S
    mBio; 2020 Mar; 11(2):. PubMed ID: 32184235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative analysis of drug resistant mutations in the reverse transcriptase domain of hepatitis B virus covalently closed circular DNA and the viral relax circle DNA].
    Su HL; Liu YM; Ren XQ; Xu DP; Zhong YW
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):818-21. PubMed ID: 21138628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.
    Ko C; Chakraborty A; Chou WM; Hasreiter J; Wettengel JM; Stadler D; Bester R; Asen T; Zhang K; Wisskirchen K; McKeating JA; Ryu WS; Protzer U
    J Hepatol; 2018 Dec; 69(6):1231-1241. PubMed ID: 30142426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parvulin 14 and Parvulin 17 Bind to HBx and cccDNA and Upregulate Hepatitis B Virus Replication from cccDNA to Virion in an HBx-Dependent Manner.
    Saeed U; Kim J; Piracha ZZ; Kwon H; Jung J; Chwae YJ; Park S; Shin HJ; Kim K
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Alternatively Spliced Sirtuin 2 Isoform 5 Inhibits Hepatitis B Virus Replication from cccDNA by Repressing Epigenetic Modifications Made by Histone Lysine Methyltransferases.
    Piracha ZZ; Saeed U; Kim J; Kwon H; Chwae YJ; Lee HW; Lim JH; Park S; Shin HJ; Kim K
    J Virol; 2020 Jul; 94(16):. PubMed ID: 32493816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation.
    Diogo Dias J; Sarica N; Neuveut C
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33925977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Tale of Usurpation and Subversion: SUMO-Dependent Integrity of Promyelocytic Leukemia Nuclear Bodies at the Crossroad of Infection and Immunity.
    Patra U; Müller S
    Front Cell Dev Biol; 2021; 9():696234. PubMed ID: 34513832
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Tu T; Zehnder B; Qu B; Urban S
    JHEP Rep; 2021 Feb; 3(1):100195. PubMed ID: 33385130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B virus X protein counteracts high mobility group box 1 protein-mediated epigenetic silencing of covalently closed circular DNA.
    Kim ES; Zhou J; Zhang H; Marchetti A; van de Klundert M; Cai D; Yu X; Mitra B; Liu Y; Wang M; Protzer U; Guo H
    PLoS Pathog; 2022 Jun; 18(6):e1010576. PubMed ID: 35679251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.